Andreas Schneeweiß

Research interests

Publications

• Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.05.801

• First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.05.355

• Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00301-6

• Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.05.801

• Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(19)30863-0

• A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz158

• Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(19)30689-8

• Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1814017

• Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer

  JAMA Oncology · 2017 · https://doi.org/10.1001/jamaoncol.2017.1007

• Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30904-x

• Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(15)00542-2

• Identification of Novel Genetic Markers of Breast Cancer Survival

  JNCI Journal of the National Cancer Institute · 2015 · https://doi.org/10.1093/jnci/djv081

• Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1413513

• Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants

  JNCI Journal of the National Cancer Institute · 2015 · https://doi.org/10.1093/jnci/djv036

• MicroRNA Related Polymorphisms and Breast Cancer Risk

  PLoS ONE · 2014 · https://doi.org/10.1371/journal.pone.0109973

• Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients

  JNCI Journal of the National Cancer Institute · 2014 · https://doi.org/10.1093/jnci/dju066

• Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(14)70160-3

• Large-scale genotyping identifies 41 new loci associated with breast cancer risk

  Nature Genetics · 2013 · https://doi.org/10.1038/ng.2563

• Genome-wide association studies identify four ER negative–specific breast cancer risk loci

  Nature Genetics · 2013 · https://doi.org/10.1038/ng.2561

• Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

  Annals of Oncology · 2013 · https://doi.org/10.1093/annonc/mdt182

• Response-Guided Neoadjuvant Chemotherapy for Breast Cancer

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.45.0940

• Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay

  Nature Biotechnology · 2013 · https://doi.org/10.1038/nbt.2576

• Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

  The Lancet Oncology · 2013 · https://doi.org/10.1016/s1470-2045(13)70130-x

• Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.46.2408

• Genome-wide association analysis identifies three new breast cancer susceptibility loci

  Nature Genetics · 2012 · https://doi.org/10.1038/ng.1049

• Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium

  Human Molecular Genetics · 2011 · https://doi.org/10.1093/hmg/ddr228

• HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial

  Breast Cancer Research and Treatment · 2010 · https://doi.org/10.1007/s10549-010-1163-x

• Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2008.21.6457

Current projects

No projects listed.